Endothelial function in patients with post-CPAP residual sleepiness

Area of Science:

• Cardiovascular Medicine
• Sleep Medicine
• Internal Medicine

Background:

• Obstructive sleep apnea (OSA) is linked to cardiovascular disease.
• Continuous positive airway pressure (CPAP) is a primary treatment for OSA.
• The impact of residual excessive daytime sleepiness (EDS) on cardiovascular health in treated OSA patients is not well understood.

Purpose of the Study:

• To compare flow-mediated dilatation (FMD) and inflammatory markers between CPAP-compliant OSA patients with and without residual EDS.
• To assess if residual EDS is associated with poorer cardiovascular markers despite adequate OSA treatment.

Main Methods:

• A comparative study involving 24 CPAP-compliant OSA patients (12 with residual EDS, 12 without) and 12 healthy controls.
• Flow-mediated dilatation (FMD) of the brachial artery was measured via ultrasound.
• Serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) were quantified.

Main Results:

• No significant differences in baseline FMD were observed among the three groups (residual EDS, no residual EDS, controls).
• Inflammatory markers (CRP, TNF-alpha, IL-6) did not differ significantly between CPAP-compliant OSA patients with and without residual EDS.
• These cardiovascular and inflammatory markers remained comparable regardless of the presence of residual EDS.

Conclusions:

• Residual excessive daytime sleepiness (EDS) in patients with adequately treated obstructive sleep apnea (OSA) does not appear to be associated with adverse cardiovascular markers.
• The findings suggest that residual EDS may not be an independent risk factor for cardiovascular diseases in this patient population.
• Further research may be warranted to fully elucidate the long-term implications of residual EDS.